Fujirebio to acquire Innogenetics from Abbott

Fujirebio, a Miraca Holdings group company, announced today a definitive agreement with Abbott, the global healthcare company, to acquire all of the issued and outstanding shares of Innogenetics, a multi-national company that develops and markets a wide range of specialty diagnostics in the fields of infectious diseases, genetic testing, transplantation as well as neuro-degeneration.

Malvern, PA, USA - July 20, 2010 - Fujirebio, a Miraca Holdings group company, announced today a definitive agreement with Abbott, the global healthcare company, to acquire all of the issued and outstanding shares of Innogenetics, a multi-national company that develops and markets a wide range of specialty diagnostics in the fields of infectious diseases, genetic testing, transplantation as well as neuro-degeneration.

> View the complete press release (PDF)